Successful Treatment of Ulcerative Colitis Associated with Hypereosinophilic Syndrome/Chronic Eosinophilic Leukemia

Nobuyasu Awano; Tomiko Ryu; Naoki Yoshimura; Masakazu Takazoe; Shigehiro Kitamura; Masanori Tanaka

doi:10.2169/internalmedicine.50.5569

CASE REPORTS

Successful Treatment of Ulcerative Colitis Associated with Hypereosinophilic Syndrome/Chronic Eosinophilic Leukemia

Nobuyasu Awano, Tomiko Ryu, Naoki Yoshimura, Masakazu Takazoe, Shigehiro Kitamura, Masanori Tanaka

Author information

Keywords: hypereosinopilic syndrome (HES), chronic eosinophilic leukemia (CEL), FIP1L1-platelet-derived growth factor receptor alpha (FIP1L1-PDGFRA), ulcerative colitis, imatinib mesylate

JOURNAL OPEN ACCESS

2011 Volume 50 Issue 16 Pages 1741-1745

DOI https://doi.org/10.2169/internalmedicine.50.5569

Details

Abstract

A 23-year-old female was diagnosed as having simultaneous ulcerative colitis (UC) relapse and hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL) without FIP1L1-platelet-derived growth factor receptor alpha (PDGFRA) (F/P) fusion gene. Pathological findings of colon specimens were compatible with UC, however, focal severe infiltration of eosinophils was observed in the rectum, which is unusual in UC, suggesting eosinophil-mediated organ damage. Although imatinib mesylate (IM) is usually ineffective for the treatment of HES/CEL with negative-F/P fusion gene, in the present case it led to the remission of HES/CEL and UC at a higher drug dosage level (400 mg/day). That suggested the presence of unknown tyrosine kinase abnormalities not yet categorized.

Corresponding author

Register with J-STAGE for free!